Research Alliance to Test CMT1A Oral Therapy in Preclinical Studies

Research Alliance to Test CMT1A Oral Therapy in Preclinical Studies

307614

Research Alliance to Test CMT1A Oral Therapy in Preclinical Studies

The Charcot-Marie-Tooth Association (CMTA) and Addex Therapeutics are teaming up to investigate a potential oral therapy for Charcot-Marie-Tooth disease type 1A (CMT1A), in rodent models of the disease. Established under the association’s Strategy to Accelerate Research (STAR), the collaboration’s goal is to study the benefits of Addex’s proprietary technology — called positive allosteric modulator (PAM) — in targeting the GABAB protein receptor, according to a press release. CMTA and Addex will work together to assess improvement of key outcomes…

You must be logged in to read/download the full post.